



# In Vivo Kinetics and Biotransformation of Aflatoxin B<sub>1</sub> in Dairy Cows Based on the Establishment of a Reliable UHPLC-MS/MS Method

Wenbo Guo<sup>1,2</sup>, Zhichen Fan<sup>2</sup>, Kai Fan<sup>2</sup>, Jijia Meng<sup>2</sup>, Dongxia Nie<sup>2</sup>, Emmanuel K. Tangni<sup>3</sup>, Zenghe Li<sup>1\*</sup>, Zhihui Zhao<sup>2</sup> and Zheng Han<sup>2\*</sup>

<sup>1</sup>School of Chemistry, Beijing University of Chemical Technology, Beijing, China, <sup>2</sup>Institute for Agro-food Standards and Testing Technology, Shanghai Key Laboratory of Protected Horticultural Technology, Shanghai Academy of Agricultural Sciences, Shanghai, China, <sup>3</sup>Organic Contaminants and Additives, Chemical and Physical Health Risks, Sciensano, Leuvensesteenweg, Brussels, Belgium

## OPEN ACCESS

### Edited by:

Vinoth Kumar Ponnusamy,  
Kaohsiung Medical University, Taiwan

### Reviewed by:

Swapnil Gurrani,  
Kaohsiung Medical University, Taiwan  
Kui Zhu,  
China Agricultural University, China

### \*Correspondence:

Zenghe Li  
lizh@mail.buct.edu.cn  
Zheng Han  
hanzheng@saas.sh.cn

### Specialty section:

This article was submitted to  
Analytical Chemistry,  
a section of the journal  
Frontiers in Chemistry

**Received:** 05 November 2021

**Accepted:** 02 December 2021

**Published:** 24 December 2021

### Citation:

Guo W, Fan Z, Fan K, Meng J, Nie D, Tangni EK, Li Z, Zhao Z and Han Z (2021) In Vivo Kinetics and Biotransformation of Aflatoxin B<sub>1</sub> in Dairy Cows Based on the Establishment of a Reliable UHPLC-MS/MS Method. *Front. Chem.* 9:809480. doi: 10.3389/fchem.2021.809480

The *in vivo* kinetics of aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) and its carry-over as aflatoxin M<sub>1</sub> (AFM<sub>1</sub>) in milk as well as the toxin loads in the tissue of dairy cows were assessed through a repetitive feeding trial of an AFB<sub>1</sub>-contaminated diet of 4 μg kg<sup>-1</sup> body weight (b.w.) for 13 days. This was followed by a clearance period that ended with a single dose trial of an AFB<sub>1</sub>-contaminated diet of 40 μg kg<sup>-1</sup> b.w. An ultra-high performance liquid chromatography tandem mass spectrometry method was developed and successfully validated by the determination of linearity ( $R^2 \geq 0.990$ ), sensitivity (lower limit of quantification, 0.1–0.2 ng ml<sup>-1</sup>), recovery (79.5–111.2%), and precision relative standard deviation (RSD) ≤14.7% in plasma, milk, and various tissues. The repetitive ingestion of AFB<sub>1</sub> indicated that the biotransformation of AFB<sub>1</sub> to AFM<sub>1</sub> occurred within 48 h, and the clearance period of AFM<sub>1</sub> in milk was not more than 2 days. The carry-over rate of AFM<sub>1</sub> in milk during the continuous ingestion experiment was in the range of 1.15–2.30% at a steady state. The *in vivo* kinetic results indicated that AFB<sub>1</sub> reached a maximum concentration of 3.8 ± 0.9 ng ml<sup>-1</sup> within 35.0 ± 10.2 min and was slowly eliminated from the plasma, with a half-life time ( $T_{1/2}$ ) of 931.1 ± 30.8 min. Meanwhile, AFM<sub>1</sub> reached a plateau in plasma (0.5 ± 0.1 ng ml<sup>-1</sup>) at 4 h after the ingestion. AFB<sub>1</sub> was found in the heart, spleen, lungs, and kidneys at concentrations of 1.6 ± 0.3, 4.1 ± 1.2, 3.3 ± 0.9 and 5.6 ± 1.4 μg kg<sup>-1</sup>, respectively. AFM<sub>1</sub> was observed in the spleen and kidneys at concentrations of only 0.7 ± 0.2 and 0.8 ± 0.1 μg kg<sup>-1</sup>, respectively. In conclusion, the *in vivo* kinetics and biotransformation of AFB<sub>1</sub> in dairy cows were determined using the developed UHPLC-MS/MS method, and the present findings could be helpful in assessing the health risks to consumers.

**Keywords:** aflatoxins, *in vivo* kinetics, biotransformation, dairy cow, UHPLC-MS/MS

## INTRODUCTION

Aflatoxin B<sub>1</sub> (AFB<sub>1</sub>), primarily produced by *Aspergillus flavus*, *Aspergillus parasiticus*, and *Aspergillus nomius*, is frequently found in different feeds and their raw materials (Kumar et al., 2016; Frazzoli et al., 2017). AFB<sub>1</sub> has been classified as a group I. Carcinogen by the International Agency for Research on Cancer (IARC) (Global Health, 2012) because of its hepatic, carcinogenic, teratogenic, mutagenic, immunosuppressive, and reproductive toxicities to livestock and poultry (Gross-Steinmeyer and Eaton, 2012; Iqbal et al., 2019). Aflatoxin M<sub>1</sub> (AFM<sub>1</sub>), derived from the 4-hydroxylated metabolite of AFB<sub>1</sub> (chemical structures shown in **Supplementary Figure S1**), is also a potential human carcinogen classified as group I by IARC (Ostry et al., 2017), and it is usually secreted into milk after the ingestion of AFB<sub>1</sub>-contaminated diets.

In recent decades, there have been many reports on the natural occurrence of AFB<sub>1</sub> in feeds and AFM<sub>1</sub> in milk and milk products (Natour et al., 1991; Han et al., 2013; Canestrari et al., 2016). The amount of AFM<sub>1</sub> in milk and AFB<sub>1</sub> in feeds consumed by animals could lead to health risks to consumers (Gonçalves et al., 2017). Therefore, the maximum AFB<sub>1</sub> limits have been set as 5 µg kg<sup>-1</sup> for compound feeds and 20 µg kg<sup>-1</sup> for all feed materials in EU (European Commission (EC), 2003), 20 µg kg<sup>-1</sup> for different feeds in the United States (Food and Agriculture Organization (FAO), 2004), and 10 µg kg<sup>-1</sup> in concentrate supplementary feeds and 50 µg kg<sup>-1</sup> in feed materials in China (State Administration for Market Regulation, 2017). For AFM<sub>1</sub>, China, several other Asian countries, and the United States have set a maximum level of 0.5 µg kg<sup>-1</sup> in raw milk and dairy products (Food and Drug Administration (FDA), 1996; ASEAN, 2015; National Health Commission of the people's Republic of China, 2017), while a considerably lower level (0.05 µg kg<sup>-1</sup>) is stipulated in the EU (European Commission (EC), 2006).

Considering the widespread occurrence and intense toxicity, the *in vivo* kinetics of AFB<sub>1</sub> have been attracting more increasing attention. A few of studies have demonstrated that dietary AFB<sub>1</sub> is rapidly absorbed into the gastrointestinal tract of different animals and partially transformed to AFM<sub>1</sub> in milk for ruminant animals, such as cows and sheep, which are the primary source of AFM<sub>1</sub> in milk (Battacone et al., 2003; Zaghini et al., 2005; Corcuera et al., 2012). The rate of dietary AFB<sub>1</sub> carry-over as AFM<sub>1</sub> in milk ranged from 0.3 to 6.2% for cows (Applebaum et al., 1982; Frobish et al., 1986) and from 1.3 to 2.9% for sheep (Battacone et al., 2005; Battacone et al., 2009). Similarly, the *in vivo* toxicokinetics of AFB<sub>1</sub> have also been studied in different model animals, including rats, mice, and monkeys (Wong and Hsieh, 1980; Bastaki et al., 2010; Corcuera et al., 2012) but not in dairy cow. To date, there is no literature on the distribution of AFB<sub>1</sub> in different tissues and organs of dairy cows, which poses potential health risks to consumers. Notably, distinct differences in previous reports about the carry-over rate and *in vivo* kinetics of AFB<sub>1</sub> in various animal species were due to differences in AFB<sub>1</sub>-delivery types, metabolic pathways, and animal susceptibility. Moreover, outdated detection methods, such as thin-layer chromatography (Stubblefield, 1986) and enzyme-linked immunosorbent assay (Diaz et al., 2004) have

occasionally resulted in discrepant and contradictory results in earlier studies owing to complex sample pretreatment, lower sensitivity, and incomplete methodology.

The main objective of this study was to develop and validate an accurate and sensitive ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method to analyze the *in vivo* kinetics and biotransformation of AFB<sub>1</sub> in AFB<sub>1</sub>-contaminated diet. Based on the model of dairy cows, the results will contribute to the understanding of the effects of dietary AFB<sub>1</sub> loads on its carry-over in milk, such as AFM<sub>1</sub>, as well as distribution, and elimination of AFB<sub>1</sub> *in vivo*. The illustration of the kinetics and biotransformation of AFB<sub>1</sub> is shown in **Supplementary Figure S2**.

## MATERIALS AND METHODS

### Chemicals and Reagents

Methanol, acetone, and acetonitrile (all HPLC grade) were purchased from Merck (Darmstadt, Germany). Ammonium acetate (HPLC grade) was obtained from Sigma-Aldrich (St. Louis, MO, United States). Water was filtered using a Millipore system (Millipore, Billerica, MA, United States). AFB<sub>1</sub> (2.03 µg ml<sup>-1</sup>), and AFM<sub>1</sub> (0.5 µg ml<sup>-1</sup>) of analytical standard were purchased from Romer Labs (Union, MO, United States).

### Preparation of Contaminated Diets

To produce AFB<sub>1</sub>-contaminated maize, an AFB<sub>1</sub>-producing strain (*Aspergillus flavus* 01) was isolated and identified at the mycotoxin research laboratory of Shanghai Academy of Agricultural Sciences, followed by cultivation on maize grains at 28°C for 28 days. The maize culture was then sterilized at 121°C, dried at 40°C for 60 h, and ground into powder. The concentrations of AFB<sub>1</sub> in contaminated maize flour and total mixed rations (TMR) feed were accurately determined according to the previously developed UHPLC-MS/MS method (Guo et al., 2017). Subsequently, 8.3 and 83 g of the obtained maize culture containing 240 mg kg<sup>-1</sup> AFB<sub>1</sub> were blended with 200 g of AFB<sub>1</sub>-free TMR feed to develop two AFB<sub>1</sub> contaminated diets: Diet A, 4 µg kg<sup>-1</sup> body weight (b.w.) and Diet B, 40 µg kg<sup>-1</sup> b.w. for the animal trials, respectively. After finishing the diets, the animals were fed AFB<sub>1</sub>-free TMR feed. The control group was directly fed AFB<sub>1</sub>-free TMR feed.

### Animals and Diet Management

Five Holstein dairy lactating cows (b.w. = 500 ± 10 kg, 30–32 weeks of calving) were purchased from Zhangxueping Dairy Farm (Nanjing, China). Before the experiments began, the dairy cows were given feed and water daily for a week for acclimatization. The dairy cows were randomly divided into an experimental group (three cows) and a control group (two cow). TMR feed (20 kg) per cow per day was administered in equal doses at 0,700 h and 1700 h according to the methods of the National Research Council to ensure milk production of ≥10 kg. The feed was divided into small portions and given to the cows several times to ensure that all feed was consumed. The health of

all the dairy cows was monitored continuously during the experimental period. This experiment was approved by the Animal Ethics Committee of Shanghai Academy of Agricultural Science (Shanghai, China) (SYXK (Hu) 2015-0007) and Zhuozhou Jierong Bio-Technology Co., Ltd. (Zhuozhou City, Hebei, China) (SYXK (Ji) 2018-003).

## Experiment Design and Sample Collection

During the carry-over trial, dairy cows were repeatedly fed with AFB<sub>1</sub>-contaminated TMR feed (4 μg kg<sup>-1</sup> b.w.) or AFB<sub>1</sub>-free TMR feed for 13 days. All the dairy cows were milked at 0,730 h and 1730 h, and the milk yield was recorded. Milk samples (10 ml) were collected twice daily according to the volume of daily milk production. All milk samples were stored at -20°C until analysis. After a 30-days clearance period, a higher single dose of AFB<sub>1</sub> in contaminated TMR feed (40 μg kg<sup>-1</sup> b.w.) was administered to the experimental cows. Successive milk samples (10 ml) were collected at 0.5, 1, 3, 6, 9, 24, 36, 48, 72, and 96 h after the administration of AFB<sub>1</sub>-contaminated diet for further carry-over analysis of AFB<sub>1</sub>. Simultaneously, 5 ml of blood from each cow was drawn from the caudal vein at 10, 35, 45, 60, 120, 180, 240, 360, 540, 720, 1,440, 2,160, and 2,880 min for the *in vivo* kinetic study of AFB<sub>1</sub>. Each blood sample was immediately collected in a heparinized tube and centrifuged at 2,739×g for 15 min. Subsequently, aliquots of plasma were transferred into clean tubes and stored at -20°C until use. After another 30-days clearance period, all the cows were sacrificed 6 h after the oral administration of AFB<sub>1</sub> (40 μg kg<sup>-1</sup> b.w.). Tissue samples from cows, including heart, liver, spleen, lung, and kidney, were collected and stored in liquid nitrogen until analysis. Blank milk, blood, and tissue samples from the control group were collected to establish the analytical method.

## UHPLC-MS/MS Analysis

After thawing at room temperature, 200 μL of milk, plasma, and tissue homogenates, which were homogenized with normal saline (1/3, m/v), were separately transferred into a 2.5-ml centrifuge tube. Acetone (1.4 ml) of was added for protein precipitation and target extraction. The mixtures were blended by vortexing for 30 s and centrifuged at 16,099 ×g for 5 min. Subsequently, 1 ml of the supernatant was evaporated under a soft stream of nitrogen gas at 40°C, and the residues were re-dissolved in 200 μL of acetonitrile/water containing 5 mmol L<sup>-1</sup> ammonium acetate (20/80, v/v). The residues were then filtered through a 0.22 μm membrane filter for UHPLC-MS/MS analysis.

UHPLC-MS/MS analysis was performed on a Waters ACQUITY UPLC system coupled with an AB SCIEX Triple Quad TM 5500 mass spectrometer. LC separation was achieved on a Poroshell EC<sub>18</sub> column (2.1 × 100 mm, 2.7 μm, Agilent, United States) with methanol (A) and 5 mmol L<sup>-1</sup> ammonium acetate (B) as the mobile phase. The flow rate was 0.4 ml min<sup>-1</sup> and a total of 8 min of gradient elution procedure was applied as follows: initial 10% A; 0.5 min, 10% A; 1.5 min, 50% A; 5.0 min, 90% A; 6.0 min, 90% A; 6.2 min, 10% A; and 8.0 min, 10% A. The injection volume was 3 μL, and the column temperature was 40°C.

Electrospray ionization was used in positive (ESI<sup>+</sup>) mode with the following parameters: ion spray voltage, 5500 V; source

temperature, 500°C; ion source gas 1 (GS1), 50 psi; ion source gas 2 (GS2), 50 psi; and collision gas (CAD), 8 psi. The multiple reaction monitoring (MRM) mode was used for the quantification and confirmation of AFB<sub>1</sub> and AFM<sub>1</sub> with the parameters listed in **Supplementary Table S1**.

## Carry-Over Analysis

The carry-over rate of AFB<sub>1</sub> to AFM<sub>1</sub> was calculated according to the following formula:

$$\text{Carry-over rate (\%)} = \frac{m_{\text{milk}} \times C_{\text{AFM}_1}}{m_{\text{TMR}} \times C_{\text{AFB}_1}} \times 100\%$$

The  $m_{\text{milk}}$  and  $m_{\text{TMR}}$  are the milk yield (kg) and quantity of AFB<sub>1</sub>-contaminated TMR feed (kg) daily, respectively.  $C_{\text{AFM}_1}$  and  $C_{\text{AFB}_1}$  are the concentrations of AFM<sub>1</sub> in milk (μg kg<sup>-1</sup>) and AFB<sub>1</sub> in the diet (μg kg<sup>-1</sup>), respectively.

The graphs of concentration–time curves were prepared using Origin 9.0. (La Jolla, CA, United States), which were then used to illustrate the carryover of AFB<sub>1</sub> and AFM<sub>1</sub> in milk. All data are presented as mean ± standard deviation (SD).

## In Vivo Kinetics and Tissue Distribution

After oral administration, *in vivo* kinetics of AFB<sub>1</sub> was performed with DAS 2.0 (Shanghai, China) using non-compartmental analysis. AUC<sub>(0-t)</sub> and AUC<sub>(0-∞)</sub> are the areas under the plasma concentration–time curve from time 0–2,160 min and infinity, respectively. MRT<sub>(0-t)</sub> and MRT<sub>(0-∞)</sub> are the mean residence times from time 0–2,160 min and infinity, respectively, where  $T_{1/2}$  is the terminal elimination half-life.  $C_0$  and  $C_{\text{max}}$  are the initial and maximal plasma concentrations, respectively.  $T_{\text{max}}$  is the time to maximal plasma concentration. All data are presented as mean ± SD.

The concentrations of AFB<sub>1</sub> and AFM<sub>1</sub> in different tissues from individual dairy cows, including the heart, liver, spleen, lungs, and kidneys were determined.

## Method Validation


The analytical method for detecting AFB<sub>1</sub> and AFM<sub>1</sub> in plasma, milk, and various tissues, such as the heart, liver, spleen, lungs, and kidneys, was validated according to the guidelines on bioanalytical method validation provided by the European Medicines Agency (Blume et al., 2011). Linearity was evaluated in neat solvent and in plasma, milk, and various tissues spiked with AFB<sub>1</sub> and AFM<sub>1</sub> at concentrations of 0.1–200 ng ml<sup>-1</sup>. The calibration curves were drawn by plotting responses *versus* analyte concentrations, and the acceptable criterion of  $R^2$  was ≥0.99. The lower limit of quantification (LLOQ) was the lowest concentration point of the calibration curves, which is typically defined as a theoretical signal-to-noise (S/N) ratio of 10. The lower limit of detection (LOD) was the lowest concentration that could be determined and defined as a theoretical S/N ratio of 3. Note that  $S/N=SD/k$ , where SD is the standard deviation of the blank ( $n = 6$ ) and  $k$  is the slope of the matrix-matched calibration curve. The recovery and precision were evaluated in blank samples spiked with LLOQ, low, intermediate, and high levels (LLOQ, 1, 50, and 200 ng ml<sup>-1</sup> for plasma and milk; LLOQ, 1, 50, and 200 μg kg<sup>-1</sup> for various tissues, respectively) of AFB<sub>1</sub> and AFM<sub>1</sub> in six replicates. RSD values on the same day and on five successive days were used to evaluate the

**TABLE 1** | Recovery and intra- and inter-day precision of AFB<sub>1</sub> and AFM<sub>1</sub> in milk, plasma, and different tissues (*n* = 6).

Sample matrix	Aflatoxin	Spiking level (ng mL <sup>-1</sup> /μg kg <sup>-1</sup> )	Recovery (mean ± SD, %)	Intra-day precision (RSD, %)	Inter-day precision (RSD, %)
Milk	AFB <sub>1</sub>	LLOQ	85.3 ± 7.5	8.8	9.8
		1	79.5 ± 8.7	10.9	11.4
		50	86.4 ± 8.1	9.3	9.5
		200	98.7 ± 9.2	9.2	10.6
	AFM <sub>1</sub>	LLOQ	102.3 ± 10.4	10.1	12.5
		1	79.8 ± 8.4	10.5	11.3
		50	88.4 ± 7.8	8.8	9.7
		200	87.5 ± 6.5	7.4	10.3
Plasma	AFB <sub>1</sub>	LLOQ	90.7 ± 8.5	9.4	12.4
		1	82.8 ± 10.2	12.3	14.7
		50	92.4 ± 8.8	9.5	11.3
		200	94.1 ± 9.9	10.5	11.6
	AFM <sub>1</sub>	LLOQ	107.9 ± 11.2	10.3	14.0
		1	94.3 ± 3.4	3.6	9.7
		50	95.3 ± 5.8	6.1	10.2
		200	96.8 ± 2.9	3.0	13.6
Heart	AFB <sub>1</sub>	LLOQ	102.5 ± 4.1	4.0	6.8
		1	88.7 ± 4.5	5.1	8.1
		50	103.5 ± 3.9	3.7	9.9
		200	92.1 ± 8.7	9.5	10.3
	AFM <sub>1</sub>	LLOQ	111.2 ± 5.0	4.5	6.9
		1	99.2 ± 10.2	10.2	9.4
		50	96.3 ± 5.3	5.5	9.1
		200	94.5 ± 9.0	9.5	9.0
Liver	AFB <sub>1</sub>	LLOQ	104.1 ± 8.4	8.0	8.9
		1	93.0 ± 11.1	11.9	10.8
		50	93.3 ± 4.4	4.7	8.3
		200	98.3 ± 8.8	9.1	7.7
	AFM <sub>1</sub>	LLOQ	109.6 ± 9.2	7.4	8.3
		1	83.3 ± 5.5	6.6	10.2
		50	91.1 ± 11.1	12.1	11.2
		200	89.0 ± 7.0	7.9	8.4
Spleen	AFB <sub>1</sub>	LLOQ	104.8 ± 9.1	8.9	8.6
		1	86.8 ± 10.1	11.6	9.4
		50	100.0 ± 11.0	11.0	8.9
		200	94.5 ± 7.7	8.1	9.3
	AFM <sub>1</sub>	LLOQ	99.9 ± 8.6	8.6	9.3
		1	87.3 ± 7.3	8.4	9.3
		50	95.2 ± 11.6	12.1	9.9
		200	87.6 ± 11.3	12.9	11.2
Lung	AFB <sub>1</sub>	LLOQ	102.4 ± 11.9	11.6	12.4
		1	93.6 ± 10.8	11.6	12.1
		50	94.5 ± 7.2	7.6	9.7
		200	85.8 ± 7.2	8.4	8.7
	AFM <sub>1</sub>	LLOQ	103.0 ± 9.4	9.1	10.1
		1	89.4 ± 8.4	9.3	9.5
		50	97.5 ± 6.6	6.7	8.4
		200	95.5 ± 6.9	7.2	8.0
Kidney	AFB <sub>1</sub>	LLOQ	100.9 ± 10.1	10.0	11.2
		1	85.1 ± 9.7	11.3	11.7
		50	94.9 ± 8.0	8.4	9.8
		200	91.4 ± 6.6	7.2	8.3
	AFM <sub>1</sub>	LLOQ	106.6 ± 6.1	5.7	8.2
		1	87.0 ± 6.4	7.3	11.2
		50	91.6 ± 5.9	6.5	8.5
		200	92.2 ± 9.2	10.0	10.8

intra- and inter-day precision, respectively. The short-term (room temperature for 8 h) and long-term (-20°C for 20 days) stability of spiked plasma and tissue samples (1 and 50 ng mL<sup>-1</sup> for plasma and

milk, 1 and 50 μg kg<sup>-1</sup> for various tissues), as well as the stability after three freeze-thaw cycles, were evaluated to ensure that the concentrations of AFB<sub>1</sub> and AFM<sub>1</sub> were not affected. In addition,




blank, spiked, and real plasma, milk, and spleen collected after AFB<sub>1</sub> oral administration were individually analyzed and evaluated for specificity.

## RESULTS AND DISCUSSION

### Optimization of Extraction Solvent

In the current study, three different solvents (methanol, acetonitrile and acetone) at different extraction volumes (0.6,




1.0, 1.4, and 1.8 ml, respectively) were compared for the spiked milk samples (50 ng ml<sup>-1</sup>). The extraction efficiency was evaluated according to the following formula:

Extraction efficiency = extraction recovery × matrix effect × 100%

As shown in **Supplementary Table S2**, the highest extraction efficiency of 77.5 and 89.4% was achieved for AFB<sub>1</sub> and AFM<sub>1</sub>, respectively, when 1.4 ml of acetone was selected. Similar trends were observed for AFB<sub>1</sub> and AFM<sub>1</sub> in plasma and different tissue samples. Therefore, 1.4 ml of acetone was selected as the extraction solvent for protein precipitation and target extraction.

### Method Validation


Good linear relationships were obtained with correlation coefficients ( $R^2$ ) > 0.99 in neat solvent and blank plasma, milk, and tissues (**Supplementary Table S3**). The LLODs and LLOQs for AFB<sub>1</sub> and AFM<sub>1</sub> in different matrices were in the range of 0.03–0.2 ng ml<sup>-1</sup> (µg kg<sup>-1</sup>) and 0.1–0.5 ng ml<sup>-1</sup> (µg kg<sup>-1</sup>), respectively. Satisfactory recoveries and precisions for AFB<sub>1</sub> and AFM<sub>1</sub> at various spiking levels are listed in **Table 1**. The recoveries ranged from 79.5 to 102.3% for milk; 82.8–107.9% for plasma; 88.7–111.2% for heart; 83.3–109.6% for liver; 86.8–104.8% for spleen; 85.8–103.0% for lung; and 85.1–106.6% for kidney. The intra- and inter-day RSDs were in the range of 3.0–12.3% and 6.8–14.7%, respectively, for various matrices, indicating the acceptable reproducibility of the



proposed method. The concentration at each spiking level of all samples after the short-term, long-term, and three freeze–thaw cycle stability tests were in the range of 82.2–102.0% (Supplementary Table S4), which indicated that AFB<sub>1</sub> and AFM<sub>1</sub> in all the biological matrices were stable. Moreover, no endogenous interference was observed at the respective retention times of AFB<sub>1</sub> (5.0 min) and AFM<sub>1</sub> (5.5 min) in plasma, milk, and spleen matrices (Figure 1), verifying the good selectivity of this method.

### Carry-Over Rate of AFB<sub>1</sub> to AFM<sub>1</sub> in Milk

The repetitive ingestion of 4 µg kg<sup>-1</sup> b.w. of AFB<sub>1</sub> for 13 days (intoxication period) demonstrated that the concentrations of AFM<sub>1</sub> in the milk increased rapidly from the first day, with concentrations remaining in the range of 2.6–3.8 µg kg<sup>-1</sup> till day 13 (Figure 2A). As presented in Supplementary Table S5, this result was similar to that previously reported in cows that were fed a diet containing ~ 86 µg AFB<sub>1</sub> daily for 7 days (Britzi et al., 2013). After the intoxication period (13 days), the cows were fed AFB<sub>1</sub>-free feeds, and the milk was collected for 7 days (clearance period). The concentration of AFM<sub>1</sub> in milk decreased gradually and could not be detected after 2 days. These results corresponded with those of previous studies that reported the clearance period typically lasted less than 3 days for AFB<sub>1</sub> (Diaz et al., 2004). As depicted in Figure 2B, the carry-over rate of



**TABLE 2** | Primary toxicokinetic parameters of AFB<sub>1</sub> after a single oral administration (40 µg kg<sup>-1</sup> b.w.) to dairy cows (*n* = 3).

Toxicokinetic parameter <sup>a</sup>	Unit	Mean ± SD
AUC (0–t)	ng min mL <sup>-1</sup> .	1763.3 ± 132.5
AUC (0–∞)	ng min mL <sup>-1</sup>	2,162.7 ± 359.6
MRT (0–t)	min	703.5 ± 56.6
MRT (0–∞)	min	1,220.7 ± 94.1
T <sub>1/2</sub>	min	931.1 ± 30.8
C <sub>0</sub>	ng mL <sup>-1</sup>	0
C <sub>max</sub>	ng mL <sup>-1</sup>	3.8 ± 0.9
T <sub>max</sub>	min	35.0 ± 10.2

<sup>a</sup>AUC<sub>0–t</sub> = area under the plasma concentration–time curve from time 0–2,160 min, AUC<sub>0–∞</sub> = area under the plasma concentration–time curve from time 0 to infinity, MRT (0–t) = mean residence time from time 0–2,160 min, MRT (0–∞) = mean residence time from time 0 to infinity; T<sub>1/2</sub> = terminal elimination half-life; C<sub>0</sub> = plasma concentration at time 0; C<sub>max</sub> = maximal plasma concentration; T<sub>max</sub> = time to maximal plasma concentration; SD, standard deviation.

AFM<sub>1</sub> in milk during the continuous ingestion experiment was in the range of 1.15–2.30% at a steady state, which was consistent with the range of 1–3% that has been reported in previous studies (Diaz et al., 2004; Van Eijkeren et al., 2006; Masoero et al., 2007) (Supplementary Table S5).

Furthermore, a high single dose (40 µg kg<sup>-1</sup> b.w.) of feed artificially contaminated with AFB<sub>1</sub> showed that AFM<sub>1</sub> in milk increased rapidly and the highest concentration of AFM<sub>1</sub> was observed at 24 h (21.3 ± 2.9 µg kg<sup>-1</sup>) (Figure 3A). After its plateau, AFM<sub>1</sub> concentration decreased rapidly and could not be detected after 96 h. The disappearance pattern of AFM<sub>1</sub> in milk is depicted in Figure 3B, and the disappearance of AFM<sub>1</sub> in milk can be expressed as:  $y = 117.95e^{-0.059x}$ ,  $R^2 = 0.9569$ . Overall, no significant differences were observed in the carry-over of AFB<sub>1</sub> to AFM<sub>1</sub> with different administration approaches and concentrations, similar to the results of previous studies on cows and sheep. However, the observed plateaus and clearance periods of AFM<sub>1</sub> in milk were partially variable (Supplementary Table S5). These variations may be related to the different dietary sources of AFB<sub>1</sub>, for example, pure AFB<sub>1</sub> or naturally

AFB<sub>1</sub>-contaminated corn, cottonseed, and ground-peanut meal, varying levels of AFB<sub>1</sub> dose, as well as the differences between individual animals (Battacone et al., 2003; Battacone et al., 2012; Sumantri et al., 2012).

## In Vivo Kinetics

The concentration–time profiles of AFB<sub>1</sub> and AFM<sub>1</sub>, as well as the toxicokinetic parameters in plasma after a single dose (40 μg kg<sup>-1</sup> b.w.) of AFB<sub>1</sub> are presented in **Figure 4** and **Table 2**. The results indicated that AFB<sub>1</sub> was rapidly absorbed in all studied cows with the highest concentrations ( $C_{\max} = 3.8 \pm 0.9$  ng ml<sup>-1</sup>) approximately 35.0 ± 10.2 min after oral administration. Meanwhile, AFB<sub>1</sub> was rapidly eliminated in cows ( $T_{1/2} = 931.1 \pm 30.8$  min) and transformed into AFM<sub>1</sub>, which plateaued in the plasma (0.5 ± 0.1 ng ml<sup>-1</sup>) at 4 h after ingestion. As presented in **Supplementary Table S5**, the values of the primary kinetic parameters in this study were significantly different from those of other animals, such as rats, mice, monkeys, and broiler chickens (Bastaki et al., 2010; Cui et al., 2017). This can be attributed to many factors, including the differences in AFB<sub>1</sub> intake, gastrointestinal absorption, animal health, and particularly in the activity of cytochrome P450 (CYP450) enzymes, which play an important role in the transformation of AFB<sub>1</sub> to AFM<sub>1</sub> in the liver (Applebaum et al., 1982; Gross-Steinmeyer and Eaton, 2012).

## Tissue Distribution

After a single oral dose of AFB<sub>1</sub> (40 μg kg<sup>-1</sup> b.w.), all tissues were analyzed *via* the validated UHPLC-MS/MS method. The concentrations of AFB<sub>1</sub> in the heart, spleen, lungs and kidneys were 1.6 ± 0.3, 4.1 ± 1.2, 3.3 ± 0.9 and 5.6 ± 1.4 μg kg<sup>-1</sup>, respectively. Although the liver is typically considered the most susceptible organ for AFB<sub>1</sub>, neither aflatoxin was detected in all the live samples. It is likely that AFB<sub>1</sub> in the liver was completely cleared because of the time taken between last feed and sacrifice (Corcuera et al., 2012; Cui et al., 2017). Moreover, AFM<sub>1</sub> was observed in the spleen and kidneys at concentrations of 0.7 ± 0.2 and 0.8 ± 0.1 μg kg<sup>-1</sup>, respectively. In summary, these results verified the effects of AFB<sub>1</sub> and AFM<sub>1</sub> accumulation in different tissues, particularly in the spleen and kidneys, which could pose health risks for both dairy cows and consumers.

## CONCLUSION

An accurate and reliable UHPLC-MS/MS method was established and validated for the simultaneous determination of AFB<sub>1</sub> and AFM<sub>1</sub> in the plasma, milk, and tissues of dairy cows. And the method was applied to investigate *in vivo* kinetics and biotransformation of AFB<sub>1</sub> in dairy cows. A rapid absorption,

distribution, and excretion of AFB<sub>1</sub> was observed in dietary cows with relatively high residues detected in kidneys, lungs, heart, and spleen. A certain amount of AFB<sub>1</sub> (1.15–2.30%) could also be transformed to AFM<sub>1</sub>, as another important risk factors and then excreted into milk. This comprehensive study will be of great value in the evaluation and control of AFB<sub>1</sub> contamination in feeds to reduce the health risks posed to both humans and animals.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

## ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Ethics Committee of Shanghai Academy of Agricultural Science (Shanghai, China) (SYXK (Hu) 2015-0007) and Zhuozhou Jierong Bio-Technology Co., Ltd. (Zhuozhou City, Hebei, China) (SYXK (Ji) 2018-003).

## AUTHOR CONTRIBUTIONS

WG and ZF performed the experiments; KF and JM contributed to the sample preparation, and WG wrote the manuscript; DN performed the data processing; ET and ZZ reviewed the manuscript; ZL and ZH conceived and designed the experiments.

## FUNDING

This work was financially supported by the National Key R&D Plan (No. 2017YFC1700806), Shanghai Rising-Star Program (21QB1403300), Science and Technology Innovation Action Plan Project of Shanghai Municipal Commission of Science and Technology (No. 17391901200), and National Natural Science Foundation of China (No. 31972178).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fchem.2021.809480/full#supplementary-material>

## REFERENCES

- Applebaum, R. S., Brackett, R. E., Wiseman, D. W., and Marth, E. H. (1982). Responses of Dairy Cows to Dietary Aflatoxin: Feed Intake and Yield, Toxin Content, and Quality of Milk of Cows Treated With Pure and Impure Aflatoxin. *J. Dairy Sci.* 65, 1503–1508. doi:10.3168/jds.s0022-0302(82)82374-6
- ASEAN (2015). *Regulatory Limits of Mycotoxins in ASEAN Countries*. Jakarta, Indonesia: Food Regulations Commission.
- Bastaki, S. A., Osman, N., Kochiyil, J., Shafiullah, M., Padmanabhan, R., and Abdulrazzaq, Y. M. (2010). Toxicokinetics of Aflatoxin in Pregnant Mice. *Int. J. Toxicol.* 29, 425–431. doi:10.1177/1091581810369565
- Battacone, G., Nudda, A., Cannas, A., Borlino, A. C., Bomboi, G., and Pulina, G. (2003). Excretion of Aflatoxin M1 in Milk of Dairy Ewes Treated With Different

- Doses of Aflatoxin B1. *J. Dairy Sci.* 86, 2667–2675. doi:10.3168/jds.s0022-0302(03)73862-4
- Battaccone, G., Nudda, A., Palomba, M., Mazzette, A., and Pulina, G. (2009). The Transfer of Aflatoxin M1 in Milk of Ewes Fed Diet Naturally Contaminated by Aflatoxins and Effect of Inclusion of Dried Yeast Culture in the Diet. *J. Dairy Sci.* 92, 4997–5004. doi:10.3168/jds.2008-1684
- Battaccone, G., Nudda, A., Palomba, M., Pascale, M., Nicolussi, P., and Pulina, G. (2005). Transfer of Aflatoxin B1 From Feed to Milk and From Milk to Curd and Whey in Dairy Sheep Fed Artificially Contaminated Concentrates. *J. Dairy Sci.* 88, 3063–3069. doi:10.3168/jds.s0022-0302(05)72987-8
- Battaccone, G., Nudda, A., Rasso, S. P. G., Decandia, M., and Pulina, G. (2012). Excretion Pattern of Aflatoxin M1 in Milk of Goats Fed a Single Dose of Aflatoxin B1. *J. Dairy Sci.* 95, 2656–2661. doi:10.3168/jds.2011-5003
- Blume, H., Brendel, E., Brudny-Klöppel, M., Grebe, S., Lausecker, B., Rohde, G., et al. (2011). Workshop/Conference Report on EMA Draft Guideline on Validation of Bioanalytical Methods. *Eur. J. Pharm. Sci.* 42, 300–305. doi:10.1016/j.ejps.2010.12.008
- Britzi, M., Friedman, S., Miron, J., Solomon, R., Cuneah, O., Shimshoni, J., et al. (2013). Carry-Over of Aflatoxin B1 to Aflatoxin M1 in High Yielding Israeli Cows in Mid- and Late-Lactation. *Toxins* 5, 173–183. doi:10.3390/toxins5010173
- Canestrari, G., Ricci, B., Pizzamiglio, V., Biancardi, A., Piazza, P., Meriardi, G., et al. (2016). Aflatoxin B1 Risk Management in Parmigiano Reggiano Dairy Cow Feed. *Ital. J. Food Saf.* 5, 5291. doi:10.4081/ijfs.2016.5291
- Corcuera, L. A., Vettorazzi, A., Arbillaga, L., González-Peñas, E., and López de Cerain, A. (2012). An Approach to the Toxicity and Toxicokinetics of Aflatoxin B1 and Ochratoxin A After Simultaneous Oral Administration to Fasted F344 Rats. *Food Chem. Toxicol.* 50, 3440–3446. doi:10.1016/j.fct.2012.06.048
- Cui, X., Muhammad, I., Li, R., Jin, H., Guo, Z., Yang, Y., et al. (2017). Development of a UPLC-FLD Method for Detection of Aflatoxin B1 and M1 in Animal Tissue to Study the Effect of Curcumin on Mycotoxin Clearance Rates. *Front. Pharmacol.* 8, 650. doi:10.3389/fphar.2017.00650
- Diaz, D. E., Hagler Jr., W. M., Blackwelder, J. T., Eve, J. A., Hopkins, B. A., Anderson, K. L., et al. (2004). Aflatoxin Binders II: Reduction of Aflatoxin M1 in Milk by Sequestering Agents of Cows Consuming Aflatoxin in Feed. *Mycopathologia* 157, 233–241. doi:10.1023/b:myco.0000020587.93872.59
- European Commission (EC) (2003). *Annex I to Directive 2002/32/EC of 1 Nov 2003 Setting Maximum Levels for Undesirable Substances in Animal Feed*. Belgium, Brussels: Official Journal of the European Communities, L285.
- European Commission (EC) (2006). *Regulation No 1881/2006 of 19 Dec 2006 Setting Maximum Levels for Certain Contaminants in Foodstuffs Official Journal of the European Communities*. Brussels: Belgium, L364.
- Food and Agriculture Organization (FAO) (2004). *Worldwide Regulations for Mycotoxins in Food and Feed in 200-A Compendium*. Rome: FAO food and nutrition meeting Italy.
- Food and Drug Administration (FDA) (1996). *Whole Milk, Low Fat Milk, Skim Milk-Aflatoxin M1 (CPG 7106.210) FDA Compliance Policy Guides*. Washington, DC: Office of Regulatory Affairs, Center for Food Safety and Applied Nutrition.
- Frazzoli, C., Gherardi, P., Saxena, N., Belluzzi, G., and Mantovani, A. (2017). The Hotspot for (Global) One Health in Primary Food Production: Aflatoxin M1 in Dairy Products. *Front. Public Health* 4, 294. doi:10.3389/fpubh.2016.00294
- Frobish, R. A., Bradley, B. D., Wagner, D. D., Long-Bradley, P. E., and Hairston, H. (1986). Aflatoxin Residues in Milk of Dairy Cows After Ingestion of Naturally Contaminated Grain. *J. Food Prot.* 49, 781–785. doi:10.4315/0362-028x-49.10.781
- Gonçalves, B. L., Gonçalves, J. L., Rosim, R. E., Cappato, L. P., Cruz, A. G. D., Oliveira, C. A. F., et al. (2017). Effects of Different Sources of *Saccharomyces cerevisiae* Biomass on Milk Production, Composition, and Aflatoxin M1 Excretion in Milk from Dairy Cows Fed Aflatoxin B1. *J. Dairy Sci.* 100, 5701–5708. doi:10.3168/jds.2016-12215
- Gross-Steinmeyer, K., and Eaton, D. L. (2012). Dietary Modulation of the Biotransformation and Genotoxicity of Aflatoxin B1. *Toxicology* 299, 69–79. doi:10.1016/j.tox.2012.05.016
- Guo, W., Wu, L., Fan, K., Nie, D., He, W., Yang, J., et al. (2017). Reduced Graphene Oxide-Gold Nanoparticle Nanoframework as a Highly Selective Separation Material for Aflatoxins. *Sci. Rep.* 7, 14484. doi:10.1038/s41598-017-15210-1
- Global Health (2012). IARC Chemical Agents and Related Occupations, A Review of Human Carcinogens. *IARC Monogr. Eval. Carcinogenic Risks Humans* 100, 9–567.
- Han, R. W., Zheng, N., Wang, J. Q., Zhen, Y. P., Xu, X. M., and Li, S. L. (2013). Survey of Aflatoxin in Dairy Cow Feed and Raw Milk in China. *Food Control* 34, 35–39. doi:10.1016/j.foodcont.2013.04.008
- Iqbal, M., Mazhar, A., Adil, M., Arif, N., and Ahmad, I. (2019). Aflatoxins Biosynthesis, Toxicity and Intervention Strategies: A Review. *Chem. Int.* 5, 168–191. doi:10.2139/ssrn.3407341
- Kumar, P., Mahato, D. K. K., Kamle, M., Mohanta, T. K. K., and Kang, S. G. G. (2016). Aflatoxins: A Global Concern for Food Safety, Human Health and Their Management. *Front. Microbiol.* 7, 2170. doi:10.3389/fmicb.2016.02170
- Masoero, F., Gallo, A., Moschini, M., Piva, G., and Diaz, D. (2007). Carryover of Aflatoxin From Feed to Milk in Dairy Cows With Low or High Somatic Cell Counts. *Animal* 1, 1344–1350. doi:10.1017/s1751731107000663
- National Health Commission of the people's Republic of China (2017). *National Food Safety Standard for Limit of Mycotoxins in Food: GB 2761-2017*. Beijing, China: Standards Press of China.
- Natour, R. M., Rabba, J. A., Nowar, M. S., Salhab, A., and Mahasneh, A. (1991). Incidence and Level of Aflatoxin M1 in Liquid and Imported Powdered Milk in Jordan With Special Reference to Aflatoxin B1 in Corresponding Feeds. *Environ. Sci. Res.* 42, 205–216. doi:10.1007/978-1-4615-3282-8\_16
- Ostry, V., Malir, F., Toman, J., and Grosse, Y. (2017). Mycotoxins as Human Carcinogens-The IARC Monographs Classification. *Mycotoxin Res.* 33, 65–73. doi:10.1007/s12550-016-0265-7
- State Administration for Market Regulation (2017). *Hygienical Standard for Feeds: GB 13078-2017*. Beijing, China: Standards Press of China.
- Stubblefield, R. D. (1986). Thin-layer and High Performance Liquid Chromatographic Methods for the Analysis of Aflatoxins in Animal Tissues and Fluids. *Diagn. Mycotoxicoses* 33, 257–269. doi:10.1007/978-94-009-4235-6\_22
- Sumantri, I., Murti, T. W., Van, d. P., Boehm, J., and Agus, A. (2012). Carry-Over of Aflatoxin B1-Feed into Aflatoxin M1-Milk in Dairy Cows Treated With Natural Sources of Aflatoxin and Bentonite. *J. Indonesian Trop. Anim. Agric.* 37, 271–277. doi:10.14710/jitaa.37.4.271-277
- Van Eijkeren, J. C. H., Bakker, M. I., and Zeilmaker, M. J. (2006). A Simple Steady-State Model for Carry-Over of Aflatoxins From Feed to Cow's Milk. *Food Additives and Contaminants* 23, 833–838. doi:10.1080/02652030600779890
- Wong, Z. A., and Hsieh, D. P. H. (1980). The Comparative Metabolism and Toxicokinetics of Aflatoxin B1 in the Monkey, Rat, and Mouse. *Toxicol. Appl. Pharmacol.* 55, 115–125. doi:10.1016/0041-008x(80)90227-6
- Zaghini, A., Martelli, G., Roncada, P., Simioli, M., and Rizzi, L. (2005). Mannanoligosaccharides and Aflatoxin B1 in Feed for Laying Hens: Effects on Egg Quality, Aflatoxins B1 and M1 Residues in Eggs, and Aflatoxin B1 Levels in Liver. *Poult. Sci.* 84, 825–832. doi:10.1093/ps/84.6.825

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Guo, Fan, Fan, Meng, Nie, Tangni, Li, Zhao and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.